Navigation Links
Men taking long-acting chronic pain meds 5xs more likely to have low testosterone levels
Date:1/31/2013

OAKLAND, Calif., January 31, 2013 Low testosterone levels occur five times more often among men who take long-acting instead of short-acting opioids for chronic pain, according to a new Kaiser Permanente study published in The Clinical Journal of Pain.

While it has been known that opioids cause low testosterone in men, this study is the first to show a significant difference in risk between short-acting (immediate release) and long-acting opioids.

The 81 men in the retrospective study were between 26 and 79 years old (median age 51) and were seen in the chronic-pain clinic at Kaiser Permanente's Santa Rosa Medical Center (Calif.) between January 2009 and June 2010. All of the participants had been on a stable dose of an opioid for at least three months, and none had a previous diagnosis of low testosterone. A larger retrospective study of more than 1,500 male pain patients is currently under way.

"There's a large gap in the evidence base with regard to opioids," said Andrea Rubinstein, MD, of the Departments of Chronic Pain and Anesthesiology, Kaiser Permanente Santa Rosa Medical Center. "More safety and efficacy studies are needed. We need to know how we can prescribe these very useful medications in a way that brings the greatest benefits to our patients, without introducing additional risks."

Once prescribed primarily to cancer patients, the use of opioid-based medications such as oxycodone (Oxycontin) and hydrocodone (Vicodin) for treating chronic, non-cancer pain has increased dramatically in recent decades. An estimated 4.3 million Americans use opioids on a daily basis for pain.

"For years, doctors have been encouraged to prescribe long-acting opioids rather than short-acting opioids because we believed they were safer, had less abuse potential, and offered more consistent pain control, but no study has ever been able to support this practice," Dr. Rubinstein said.

The study compared the use of short-acting opioids, which immediately release the pain medication and are taken every four to six hours, and long-acting opioids, which slowly release the pain medication and are taken every eight to 12 hours.

A healthy young man should have testosterone levels between 300 and 800 nanograms per deciliter (ng/dL); in this study, low testosterone, also known as hypogonadism, was defined as less than 250 ng/dL. Low testosterone levels have been associated with decreases in muscle mass, bone density (osteoporosis or osteopenia), cognition, mood, libido (sex drive) and general quality of life.

Seventy-four percent of the men on long-acting opioids had low testosterone levels, compared with 34 percent of the men using short-acting opioids. After controlling for daily dosage and body mass index, the study found that the odds of having low testosterone were 4.78 times greater for men taking a long-acting opioid than a short-acting opioid. Dose was not associated with an increased risk of low testosterone.

"These medications work well for short-term, acute pain," said Dr. Rubinstein. "It has long been extrapolated that they can also be used safely long-term to control chronic pain. We are now finding that the long-term use of opioids may have important unintended health consequences."


'/>"/>

Contact: Vincent Staupe
vstaupe@golinharris.com
415-318-4386
Kaiser Permanente
Source:Eurekalert

Related medicine news :

1. The US Drug Watchdog Now Urges Young Women Who Suffered a Heart Attack or Blood Clotting After Taking Yaz or Yasmin Birth Control Pills to Contact the Johnson Law Group
2. Eat Too Much While Watching TV? Try Taking Smaller Bites
3. Why good resolutions about taking up a physical activity can be hard to keep
4. Mistaking OCD for ADHD has serious consequences
5. Gen X overtaking baby boomers on obesity
6. Millions May Be Taking Vitamin D Unnecessarily, Analysis Suggests
7. Year of Taking Risky Blood Thinners May Be Unnecessary After Stent Surgery
8. Taking Breaks From Prostate Cancer Hormone Therapy Seems Safe: Study
9. Children taking steroids for asthma are slightly shorter than peers
10. Many Teens Drinking, Taking Drugs During School: Survey
11. More Kids Taking Antipsychotics for ADHD: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... ... Harbour , a DAO (decentralized autonomous organization) that harnesses the wisdom of ... technical specifications . , 2017 has seen an explosion of token launches by blockchain ... will garner the greatest ROI. Dean Eigenmann, Co-founder and CEO of Harbour, said, “We ...
(Date:6/27/2017)... ... June 27, 2017 , ... From June 20-22, EarQ and Widex ... Syracuse, New York, where EarQ is headquartered. , Together, the organizations educate hearing ... today’s savvy consumer, and the latest in hearing technology. At the event, EarQ ...
(Date:6/27/2017)... ... June 27, 2017 , ... PR ... an upcoming case studies guidebook. This guidebook offers an excellent branding and exposure ... include articles, case studies and how-to’s that fall into the following categories:, ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... Hammer Strength, ... Association (NBSCA) have named Javair Gillett of the Houston Rockets the NBSCA Strength & ... the award is decided by NBSCA members who vote to select the coach who ...
(Date:6/27/2017)... ... June 27, 2017 , ... Children’s National Health System ... rankings, with its Neonatology program ranking #1 out of more than 1500 neonatal ... to the coveted Honor Roll, a distinction given to the top performing children’s hospitals ...
Breaking Medicine News(10 mins):
(Date:6/19/2017)... 2017  Researchers from DRUGSCAN ® and INC ... a live, complimentary webinar titled, "Untangling methods to tamper ... real world" on Wednesday June 28, 2017 from 12:00 ... webinar will feature interviews with recreational and dependent prescription ... techniques abusers use to prepare opioid tablets for routes ...
(Date:6/14/2017)... , June 14, 2017 The Bio ... City of Fremont and the ... the bio-pharma industry in California ... enabling executive networking, and fostering workforce development. The primary ... and growth of start-ups, as well as small and ...
(Date:6/11/2017)... , June 10, 2017  Eli Lilly and Company ... from three Phase 3 studies of galcanezumab, an investigational ... including late-breaking data on several key secondary endpoints for ... results from these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will ... annual scientific meeting in Boston . ...
Breaking Medicine Technology: